Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02096 SIMCERE PHARMA
RTNominal up5.300 +0.060 (+1.145%)
Others

08/12/2021 15:39

Simcere Pharma (02096) gets clinical trial approvals

[ET Net News Agency, 8 December 2021] Simcere Pharmaceutical Group Limited (02096) said
SIM0235 (SIM1811-03 injection), a humanized anti-tumour necrosis factor receptor 2 (TNFR2)
monoclonal antibody independently developed by the group, has obtained the clinical trial
approval issued by the National Medical Products Administration, PRC, which is intended to
be used for clinical trials of relapsed or refractory advanced solid tumours and cutaneous
T-cell lymphoma (CTCL).
Also, SIM0395 (Paxalisib), an innovative drug developed under the collaboration of the
company and Kazia Therapeutics Limited, has obtained the clinical trial approval issued by
the National Medical Products Administration, PRC for the treatment of glioblastoma (GBM)
covering patients of new diagnosis and relapse. (RC)

Back to Others

Remark: Real time quote last updated: 26/04/2024 16:55
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.